Macrocyclic Peptides for Amyloid Misfolding and Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for protein misfolding diseases such as ALS and Alzheimer's disease are inadequate, with existing therapies only providing minor delays in disease progression and significant side effects, highlighting the need for novel and cost-effective approaches to modulate protein misfolding and aggregation.
Innovation Solution
A bacterial platform is developed to biosynthetically produce large combinatorial libraries of macrocyclic compounds in E. coli cells, which are then screened using a high-throughput genetic assay to identify compounds that rescue the misfolding and aggregation of proteins like Cu/Zn superoxide dismutase and β-amyloid peptide, utilizing cyclic oligopeptides with specific modifications to inhibit aggregation and neurotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for protein misfolding diseases, then disease progression is delayed slightly, but significant side effects occur and treatment effectiveness is limited
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that bind to misfolding-prone proteins and modulate their conformational stability. These small molecules act as mediators between the cellular environment and the misfolding proteins, preventing pathological aggregation while avoiding the immunogenicity and manufacturing complexity of biologics. The small molecules stabilize the native conformation of proteins like SOD1 and prevent formation of toxic aggregates, thereby treating neurodegenerative diseases with improved safety profile.
Solution Approach 2:
The patent employs high-throughput screening to identify small molecule compounds that specifically alter the conformational parameters of misfolding-prone proteins. By changing physical-chemical parameters such as conformational stability, aggregation propensity, and solubility through small molecule binding, the invention achieves therapeutic effect. The screening process measures changes in fluorescence, solubility, and aggregation state to identify compounds that optimize these parameters for disease treatment.
2Productivity
If conventional screening methods are used to identify therapeutic compounds, then screening process is simple, but throughput is low and discovery time is extended
Solution Approach 1:
The patent merges multiple screening functions into an integrated high-throughput platform that combines compound library delivery, automated imaging, and data analysis systems. The screening system integrates fluorescence detection, solubility assessment, and aggregation monitoring into a single automated workflow, enabling simultaneous evaluation of multiple compound properties across large libraries. This merged system achieves high throughput by processing thousands of compounds through coordinated robotic and analytical components.
Solution Approach 2:
The patent replaces manual, mechanical screening operations with automated imaging and computational analysis systems. Instead of conventional microplate reading and manual observation, the invention uses high-content imaging systems with automated field scanning, image processing algorithms, and machine learning-based compound identification. This substitution of mechanical operations with automated sensing and computational methods dramatically increases screening throughput while reducing human intervention.
3Ease of manufacture
If misfolding-prone proteins are expressed in bacterial systems, then production cost is reduced, but protein aggregation and misfolding increase
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that bind to misfolding-prone proteins expressed in bacterial systems and stabilize their native conformation. These small molecules act as molecular chaperones, preventing aggregation and maintaining solubility of proteins like SOD1 during bacterial expression. By adding these stabilizing intermediaries, the system achieves both cost-effective bacterial production and proper protein folding, resolving the contradiction between low-cost manufacturing and protein stability.
Solution Approach 2:
The patent applies preliminary stabilization measures during the protein expression process by co-expressing small molecules or using expression conditions that prevent misfolding before it occurs. The system incorporates preventive strategies such as optimized expression timing, temperature control, and small molecule addition during critical folding stages. This preliminary action prevents aggregation from occurring in the first place, maintaining protein stability throughout the low-cost bacterial production process.
Data Source
AI summary
Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.